SER
SER
AMEX · Biotechnology

Serina Therapeutics Inc.

$1.72
+0.16 (+10.26%)
As of May 16, 2:25 AM ET ·
Financial Highlights (FY 2026)
Revenue
181.8K
Net Income
-26,740,729
Gross Margin
71.8%
Profit Margin
-14,755.4%
Rev Growth
+63.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 71.8% 71.8% 66.4% 66.4%
Operating Margin -17,921.5% -16,129.5% -27.0% -31.0%
Profit Margin -14,755.4% -14,017.6% -29.1% -28.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 181.8K 111.5K 4.38M 4.18M
Gross Profit 130.6K 80.1K 2.91M 2.78M
Operating Income -32,587,094 -17,989,563 -1,184,186 -1,293,566
Net Income -26,740,729 -14,762,102 -1,275,702 -1,196,723
Gross Margin 71.8% 71.8% 66.4% 66.4%
Operating Margin -17,921.5% -16,129.5% -27.0% -31.0%
Profit Margin -14,755.4% -14,017.6% -29.1% -28.6%
Rev Growth +63.0% +63.0% +7.3% +19.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 3.35M 3.27M
Total Equity 12.66M 11.81M
D/E Ratio 0.26 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -26,362,859 -15,362,029 -1,970,058 -1,901,119
Free Cash Flow -1,043,157 -876,007